Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases… Avalyn Pharma is based in Boston, MA and was founded in 2011. It is valued at about $155 million as of Oct 2026, set by institutional fund marks. It has raised $387 million.
PMV mark · valuation
$155.0M
Oct 2026
Priced at
—
Total raised
$386.7M
Last round
—
Cap table — not yet on record
Avalyn Pharma's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
